Conclusion
The study of T2D-TB comorbidity from the immunoendocrine point of view
is of utmost importance to understand the background of this binomial,
as well as to propose better strategies for the control of this
comorbidity. Active GCs represent a negative factor in the development
of both entities, with a negative effect on glucose metabolism and the
development of a non-protective immune response. Treatment with BEA
represents a novel strategy as an adjuvant in the treatment of TB alone
and comorbidity with T2D. For these reasons, it is of utmost importance
to continue with the study of the BEA through its escalation to clinical
studies to be used in patients.